Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MM's calling the momo exit. Not where we'll settle, but its where we're going. I'll be up up and away, up up and away.
Clicking on the Todos Medical Link on the sponsor page takes you to my tollovid .com
News: Tollovir Data Jan 27 AM. AH CC.
Share Structure
Market Cap Market Cap
50,050,559
01/10/2022
Authorized Shares
5,000,000,000
01/07/2022
Outstanding Shares
975,644,432
01/07/2022
Restricted
164,254,783
01/07/2022
Unrestricted
811,389,649
01/07/2022
Held at DTC
765,712,075
01/07/2022
Float
607,858,204
11/18/2021
Par Value
0.01
He crushed it, but no time for Tollovir
Rephrasing in a more responsible way, since I'm the one who broke the story: The conference Todos and thousands of other professionals were scheduled to attend has been rescheduled for summer due to Omicron.
Ah so now you impune the honor of Dr. Urano?
Yes, shortly thereafter, a tragedy of finance occurred and many people suffered.
I believe on positve phase 2 data we will open at $0.12 and close at $.18. A few weeks later, after some other news, I think we will get a massive Q4 10Q with a conference call that answers Q1 revenue projections and we have built up to a close at $.35, which is a pretty reasonable market cap at $350M. From there, I think we will set the R/S at 1:25 and uplist around $9 with a final O/S of 45M and A/S of 200M shares after the capital raise end of March that will fall alongside a 10-k. That will mean we have $50-60M of cash in the bank to run a full phase 3 and rapidly progress Videssa in 2022. That's why spelling out Videssa plans will be crucial.
For the other poster, we've still got to be at $4 to meet standard 4.
New Research - MANF is protective in Charcot-Marie-Tooth disease (CMT), one of the most common inherited neurological disorders, affecting an estimated 2.6M people worldwide. There is no cure. Published in the Landmark Edition of Frontiers in Bioscience following research funded by funded by the National Natural Science Foundation of China.
Front. Biosci. (Landmark Ed). 2022; 27(1): 001
10.52586/j.fbl2701001
https://venus-pro-bucket.s3-accelerate.amazonaws.com/journal/FBL/27/1/10.52586/j.fbl2701001/2768-6698-27-1-001.pdf
New Research - MANF is protective in Charcot-Marie-Tooth disease (CMT), one of the most common inherited neurological disorders, affecting an estimated 2.6M people worldwide. There is no cure. Published in the Landmark Edition of Frontiers in Bioscience following research funded by funded by the National Natural Science Foundation of China.
Front. Biosci. (Landmark Ed). 2022; 27(1): 001
10.52586/j.fbl2701001
Yes, his lavish lifestyle working away from family, out of his car and weworks....
That's not what he said/meant. He had the 9 months through Sep 2021 up.
Just being real. I'm long strong Donkey Kong, but that doesn't mean we should ignore the risk. I won't re-explain, but there's a reason BP left this goal wide open for us.
Hey shout out in advance to any of you bear bumpkins with an under-DD'd sense of self-importance who ask dumb questions and make yourselves look like tools today. You know who you are. Slow down, GFY, and ask a decent question politely. Do it for the founding fathers.
We should be concerned with our mechanism in the hospital setting. It may be too late for the protease effect to turn things around. We could get mixed data if that's the case, which won't mean it doesn't work, but will hurt us. However, if we are super effective, AND they can demonstrate the cytokine storm and other special properties we will have a grand-slam. Risk reward.
it's data lock - and I would suggest price converges around .07 going into Jan 26 data release.
You are not looking at the right conference. There is a separate conference to be announced different thant PMWC. PMWC he presents on 28th
AMBS owns around 8% of Todos
More misleading. The Chairman's blog was a completely independent media platform Gerald used for years. The blog ceased existing sometime in the mid 2010's. EVERY SINGLE POST, FROM EVERY SINGLE USER AND COMPANY no longer exists. Gerald didn't take said blog off the internet lol #fakenews
I mean look, I'm a Yeezy guy, but I Drake ain't illegal bro
I'd say the tweet was prescient. There's been a lot of experimenting over the last 6 years lol
what's the view like from up your bum Japers?
Tell these fine folks about the time you embellished your credentials and made yourself look like a fool as you tried to take over a corporate conference call. For you to assault G's integrity is a joke. Tell them how you lost your mother's inheritance on a penny stock. Sad.
All these people have to do is look though you, Sid and the bands series of racist tweets over the years to discredit your perspective. We are still on the field with shots on goal despite your crystal ball.
Forgive yourself and you might just find the ability to forgive GC for his naive mistakes 6 years ago.
How dare you suggest JP take accountability for his own actions. If he did, he might move in with his life.
From Valentino's linkedIn, he's not retirement age, he's probably in his upper 30's. He's been at Todos for almost a month by now and is leading the hiring of 4 new marketing positions at Todos. He's been teaching at LIU for 6 years concurrently with working these other notable jobs. Prior to that he was working and teaching at NYCU. He left Novartis in April after about a year and change and worked about equally long at Merck each. He also worked at McCann and other places. He's got key certs in html, SEO, and Google Analytics that it appears he earned since leaving Novartis.
15M shares for 5 months of professional PR
I think everyone recognizes odds of major marketability post this trial are slim. MAybe we'll get lucky EUAs in a few small markets.
That said, the argument is that this is so safe, countries will take the risk. The other argument is, why wouldn't a major partner step in on good data and do just that - a quick, major p3 trial. It's potential turnkey attempt at billions in revenue.
There was no notable Tollovid data reported on a quarter to date, hence no data.
It's a part of the re-org/transaction. Chariman has spoken to this many times on twitter. For now you'll have to rely on filings.
Patients who receive treatment with the NLC-V study product depending on the weight of the patients, as follows - Patients weighing less than 70 kg will receive 2 capsules, 4 times a day (80 mg in total per day) Patients weighing between 70 kg and 100 Kg will receive 3 capsules, 4 times a day (a total of 120 mg per day). Patients weighing over 100 kg will receive 4 capsules, 4 times a day (a total of 160 mg per day). NLC-V capsules Will be taken during days 1-10 for the patient's hospitalization NLC-V capsules will be taken during days 1-10 for the patient's hospitalization
Patients who receive placebo in addition to the usual treatment for COVID-19. The placebo consists of the same solvent, but without the active ingredients of NLC-V. Placebo will be given to patients in the same manner and with the same frequency as
Inclusion criteria
Men and women aged 18 (inclusive) and up.
SARS-CoV-2 infection is confirmed by RT-PCR.
A patient is hospitalized with COVID-19 in moderately stable condition up to the upper range of a severe condition (i.e., without the need for a complete respiratory assessment).
Oxidation <96%.
Subjects must be supervised or admitted to a controlled facility or hospital due to health / respiratory infection only (home isolation is not sufficient).
Exclusion criteria
Tube feed or parenteral feed.
Respiratory imbalance requiring artificial respiration.
Pregnant or breastfeeding women.
A condition that, in the opinion of the principal investigator, would prevent full participation in this trial or interfere with the evaluation of the evaluation metrics of the trial (e.g., social status or other unrelated medical illness).
Has severe allergic reactions to one of the components of the study drug.
Active TB infection (TB).
Subjects suspected of having concomitant active infection: Bacterial, fungal, viral or other non-COVID-19 infection.
According to the researcher, the progression of the disease to death is imminent and inevitable within the next 24-36 hours, regardless of the provision of treatments.
Treatment with drugs that suppress or regulate the immune system (including tocilizumab) during the last three months (steroids are allowed).
Participation in another clinical trial of the drug.
Estimated glomerular filtration rate (eGFR) <30 ml / min (including patients receiving hemodialysis or hemofiltration).
Alanine aminotransferase (ALT) or aminotransferase aspartate (AST)> 5 x ULN is detected within 24 hours of filtration (depending on local laboratory reference range).
General neutrophil count (ANC) <1000 / microliter at filtration.
Platelet count <50,000 / microliter at filtration.
Body weight <40 kg or> 120 kg.
Treatment with another study drug within 5 half-lives or 30 days (whichever is longer) after randomized assignment.
Admission requirements (inclusion and exclusion criteria) of participants in the published clinical trials in the database are only partial, and there may be differences in admission conditions between different medical centers.
Number of participants in the country
77
Number of participants in the world
Requirements from the study participant
The duration of the study is up to 30 days, including a treatment period of 10 days and a follow-up period until the end on day 15, or until discharge from the hospital, which occurs later. In case of discharge from the hospital during the study period (before day 15), follow-up will continue until day 15. In case of prolonged hospitalization beyond 15 days, monitoring of subjects for abnormal events will continue until release, and on day 30 (phone call).
https://my.health.gov.il/CliniTrials/Pages/MOH_2021-01-20_009687.aspx
You're getting your wish JP. New AMBS CEO inbound per GC on twitter. Who do you think? Modi? Mike? Elise? Paula? David? Charlotte? Others?
Here we are at the end of 2020. Both sides said it couldn't be done. We said it wouldn't get to the trips. It did. They said it's would be sold off in a fire sale, long ago. It didn't.
The past is the past. Or is it. Same CEO. Same assets. Same financial struggle. But what does the future hold when MANF is more valuable than ever, the first spin-off is soon to bear fruit, and our largest debt is about to be unenforceable?
Happy 2021 to the scumbags and the noble fools alike. Cheers!
MANF is worthless? Be serious.
Still here, still loading. It's 2020. It's the year JP has been saying we won't take off til for 5 years now. You have to be excited.
10-k for 2019, along with all prior 10-ks on sec.gov
Penny, I'm not going to do the work for you all the time, but happy to this time. In summary, AMBS owns 85M out of anywhere between 300-350M shares depending on how much is sold to Lincoln Park over the new agreement. From the 8/20/20 Lincoln Park Prospectus at the link below:
https://www.sec.gov/Archives/edgar/data/1645260/000149315220016362/form424b4.htm
At our 2019 annual meeting of shareholders, our shareholders approved a resolution authorizing us to exercise our option to acquire the remaining 80.01% of Breakthrough from Amarantus in exchange for an additional 30% of our then issued and outstanding Ordinary Shares. On July 28, 2020, the Company entered into Amendment No. 1 to the Binding Joint Venture Agreement with Amarantus pursuant to which the parties agreed that the Company would issue 49.9% of its ordinary shares as of December 31, 2019 to Amarantus in exchange for the 80.01% equity interest it does not own of Breakthrough Diagnostics, Inc. In addition, Amarantus will receive a 10% royalty on LymPro intellectual property. The Breakthrough transaction closed on July 28, 2020. As part of the closing, we issued to Amarantus another 67,599,796 ordinary shares, giving Amarantus a total of 85,586,795 ordinary shares (which equals 49.9% of the ordinary shares that were outstanding as of December 31, 2019). Breakthrough is a joint venture we formed with Amarantus to gain ownership of exclusive worldwide rights to the Alzheimer’s blood test called the Lymphocyte Proliferation Test (LymPro Test™). Taken together with our core TBIA FTIR-based platform, we believe Todos is positioned to become the worldwide leader in the field of immune-based diagnostics. The Company formed the subsidiary Todos Medical Singapore Ltd. for the purpose of advancing clinical trials of the Company’s core technology for breast cancer in Southeast Asia.
....
As of July 31, 2020, we had approximately 294,546,835 ordinary shares outstanding, of which approximately 159,897,855 shares were held by non-affiliates. On August 4, 2020, we issued 3,500,000 ordinary shares to the funding source for a purchase order financing. On August, 5, 2020, we issued 9,250,000 shares to Lincoln Park under the Purchase Agreement. Although the Purchase Agreement provides that we may sell up to an additional $10,000,000 of our ordinary shares to Lincoln Park, only an additional 40,750,000 of our ordinary shares are being offered under this prospectus, which may be issued to Lincoln Park in the future under the Purchase Agreement, if and when we sell shares to Lincoln Park under the Purchase Agreement. If all of the 50,000,000 shares offered by Lincoln Park under this prospectus were issued and outstanding as of the date hereof, such shares would represent 14.4% of the total number of our ordinary shares outstanding and 26.6% of the total number of outstanding shares held by non-affiliates, in each case as of the date hereof. Depending on the price per share at which we sell our ordinary shares to Lincoln Park, we may be authorized to issue and sell to Lincoln Park under the Purchase Agreement more our ordinary shares than are offered under this prospectus. In that event, if we desire to issue and/or sell to Lincoln Park more than the 50,000,000 shares offered under this prospectus, we must first register for resale under the Securities Act any such additional shares, which could cause additional substantial dilution to our shareholders. The number of shares ultimately offered for resale by Lincoln Park under this prospectus is dependent upon the number of shares we direct Lincoln Park to purchase under the Purchase Agreement.
AMBS does not own 49% of Todos shares. It owns approximately 25%. Still very good though.
Don't let him change the subject. I listened to that call from a library, so many years ago. I know jpetro's voice. I've heard his split tongue.
A crime was committed against us. To his credit, j understood what was coming when the rest of us did not. But that's because he is an always will be a snake in the grass.
olds balls. that explains a lot.
Hmmm those two numbers. There's something interesting there. They're exactly 25 million shares apart ... Interesting. Did something happen last month with 25 million shares? Something that for the first time ever will put revenue on the books?
That's what you call a big dick day.
Outstanding Shares
280,290,256
02/03/2020
Japers: 20,000 posts
El Cid: 5,000 posts
Me, a spammer: 300 posts
You can't make this up. Hey I'll do you guys a favor, I'll even add in my posts from the other rag, most of which have some substance. You know, links, on topic thoughts. Not mindless hateful drivel. I've made 1,300 posts over the last 6 years. Less than 1 post a day. I have been happy to share my honest thoughts that enhance the knowledge base of anyone interested in AMBS. No shame.